Spontaneous intracerebral hematomas (ICH) are the most deadly form of stroke. Treatment options include admission to a specialized stroke unit and treatment of hypertension in the acute stage. However, both of these options have exhibited limited effectiveness. The RICH biobank collects biomaterial (DNA, plasma, serum and PAXgene) from patients with spontaneous ICH at different times in the first week after the bleeding, in order to:
1) gain insight into the role of inflammation in the development of secondary brain damage;
2) be able to explore different anti-inflammatory drugs in an ex vivo model for potential effectiveness, determined by the macrophage cytokine production capacity;
3) evaluate the effect of anti-inflammatory drug treatment in a phase II trial on markers of systemic inflammation;
4) to evaluate the effect of minimally invasive neurosurgical defecation of ICH versus regular treatment in a phase III trial on markers of systemic inflammation.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Quality certificate for the PBMC isolation method and cfDNA extraction method8 August 2023
Last year the Radboud Biobank participated for the first time in the IBBL Biospecimen Proficiency Testing program; an external quality assessment tool to verify the precision and accuracy of biospecimen testing methods and the efficiency of processing methods.read more
Theme Biobank and collections of Health RI launched a new project to develop a novel Dutch Biobank Standard30 March 2023
In February 2023 the theme Biobanks and Collections of Health-RI launched a new project entitled: “Dutch biobanking standard: towards harmonized, evidence-based collection, processing and storage of human biomaterials”.read more
Health-RI receives definitive follow-up funding from the National Growth Fund30 March 2023
The full funding of a total of 69 million euros has been definitively awarded to Health-RI, the national health data infrastructure for research and innovation.read more